{"id":5960,"date":"2025-04-23T07:44:00","date_gmt":"2025-04-22T23:44:00","guid":{"rendered":"http:\/\/www.yuntou8.com\/?p=5960"},"modified":"2025-04-24T15:37:55","modified_gmt":"2025-04-24T07:37:55","slug":"%e5%88%9b%e6%96%b0%e8%8d%af%ef%bc%8c%e5%8f%98%e5%a4%a9%e4%ba%86","status":"publish","type":"post","link":"http:\/\/www.yuntou8.com\/?p=5960","title":{"rendered":"\u521b\u65b0\u836f\uff0c\u53d8\u5929\u4e86"},"content":{"rendered":"

\u6700\u8fd1\u6570\u65e5\uff0cADC\u836f\u7269\u65b9\u9762\u7684\u597d\u6d88\u606f\u63a5\u8fde\u4e0d\u65ad\u3002,\u963f\u65af\u5229\u5eb7\/*\u4e09\u5171\u65b9\u9762\uff0c4\u670821\u65e5\uff0c\u5176\u5ba3\u5e03DS-8201\u8054\u7528\u5e15\u59a5\u73e0\u5355\u6297\u5728HER2\u9633\u6027\u7684\u4e73\u817a\u764c\u4e00\u7ebf\u6cbb\u7597\u4e2d\u51fb\u8d25\u4e86\u00a0THP\uff08\u7d2b\u6749\u70f7\u3001\u66f2\u59a5\u73e0\u5355\u6297\u548c\u5e15\u59a5\u73e0\u5355\u6297\u7597\u6cd5\uff09\u3002\u8fd9\u53ef\u4ee5\u8bf4\u662f\u4e00\u4e2a\u91cc\u7a0b\u7891\u5f0f\u7684\u4e8b\u4ef6\uff0c\u5c06DS-8201\u8fdb\u4e00\u6b65\u5411\u4e00\u7ebf\u6cbb\u7597\u63a8\u8fdb\u3002,\u5409\u5229\u5fb7\u65b9\u9762\uff0ctrodelvy\u4e5f\u51fa\u4e86\u597d\u6d88\u606f\u30024\u670821\u65e5\uff0c\u5409\u5229\u5fb7\u5ba3\u5e03trodelvy\u8054\u5408K\u836f\u5728\u4e00\u7ebf\u6cbb\u7597\u4e09\u9634\u6027\u4e73\u817a\u764c\u4e2d\u5927\u83b7\u6210\u529f\uff0c\u4e3b\u8981\u7ec8\u70b9mPFS\u76f8\u6bd4\u4e8e\u5316\u7597+PD-1\u5bf9\u7167\u7ec4\u663e\u8457\u5ef6\u957f\u3002\u8fd9\u4e5f\u662f\u4e00\u4e2a\u91cc\u7a0b\u7891\u5f0f\u7684\u4e8b\u4ef6\uff0c\u6807\u5fd7\u7740IO\uff0bADC\u7597\u6cd5\u5728\u5b9e\u4f53\u7624\u65b9\u5411\u5f7b\u5e95\u6323\u8131\u4e86\u684e\u688f\uff0c\u8fdb\u5165\u4e86\u4e00\u7ebf\u6cbb\u7597\u9636\u6bb5\u3002,\u6700\u8fd1\u7684\u4e00\u4e9b\u4e8b\u4ef6\u603b\u4f53\u6765\u770b\uff0c\u524d\u666f\u90fd\u662fADC\u7684\u8054\u7528\u5728\u5411\u4e00\u7ebf\u6cbb\u7597\u63a8\u8fdb\uff0c\u800c\u8fd9\u4e5f\u662f\u672a\u6765\u7684\u603b\u4f53\u8d8b\u52bf\uff0c\u76f8\u5bf9\u4f4e\u6bd2\u7684ADC\u53d6\u4ee3\u9ad8\u6bd2\u7684\u5316\u7597\uff0c\u4e0ePD-1\u6216\u8005\u5176\u5b83\u7c7b\u578b\u7684\u5355\u6297\u8054\u7528\uff0c\u62ff\u5230\u66f4\u4e3a\u5e7f\u5927\u7684\u5e02\u573a\u3002,\u518d\u4ece\u5927\u683c\u5c40\u53bb\u770b\uff0c\u8fd9\u610f\u5473\u7740\u521b\u65b0\u836f\u5e02\u573a\u7684\u6574\u4f53\u6539\u53d8\uff0cADC\u5c06\u4e3a\u80bf\u7624\u6cbb\u7597\u5e26\u6765\u4e00\u4e2a\u65b0\u7684\u65f6\u4ee3\u3002,01<\/strong>,\u6d88\u606f\u9762\u7684\u5206\u6790<\/strong>,\u9996\u5148\u662fDS-8201\u8054\u7528\u5e15\u59a5\u73e0\u5355\u6297\u7684\u6d88\u606f\uff0c\u5e15\u59a5\u73e0\u5355\u6297\u662fher2\u5355\u6297\uff0c2012\u5e74\u83b7\u5f97FDA\u6279\u51c6\u4e0a\u5e02\uff0c\u7b97\u662f\u4e0a\u4e00\u4e2a\u65f6\u4ee3\u5927\u5206\u5b50\u9776\u5411\u6cbb\u7597\u7684\u4e00\u4e2a\u63a2\u7d22\uff0c\u8be5\u836f\u5728her\u9633\u6027\u4e73\u817a\u764c\u65b9\u9762\u7684\u529f\u7ee9\u4e0d\u53ef\u78e8\u706d\uff0c2020\u5e74\uff0c\u5b83\u7684\u9500\u552e\u989d\u5df2\u7ecf\u8fbe\u5230\u4e8641.39\u4ebf\u7f8e\u5143\uff0c\u8fd9\u4e3b\u8981\u662f\u5c31\u662f\u9760her2\u9633\u6027\u4e73\u817a\u764c\u9002\u5e94\u75c7\u65a9\u83b7\u7684\u3002,\u518d\u8bf4\u8fd9\u4e2a\u8054\u7528\u65b9\u6848\u2014\u2014THP\u3002\u8fd9\u91cc\u6211\u4eec\u6765\u770b\u5b83\u4e00\u7ebf\u6cbb\u7597\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u6587\u732e\u3002\u5982\u56fe\u6240\u793a\uff0c\u5bf9\u4e8e\u4e00\u7ebf\u6cbb\u7597\u4e73\u817a\u764c\u800c\u8a00\uff0cmOS\u8fbe\u5230\u4e8658.3\u4e2a\u6708\uff0cmPFS\u8fbe\u5230\u4e8619.1\u4e2a\u6708\u3002\u8fd9\u5927\u6982\u5c31\u662f\u6b64\u524d\u901a\u8fc7\u4e09\u836f\u8054\u7528\u2014\u2014\u4e24\u4e2aher2\u6297\u4f53\u52a0\u4e00\u4e2a\u5316\u7597\u836f\u7269\u7528\u5728\u4e73\u817a\u764c\u8eab\u4e0a\u80fd\u591f\u8fbe\u5230\u7684\u6548\u679c\u3002,\"2025423819549933\",\uff08\u56fe\u7247\u6765\u6e90\uff1aReal-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer\uff09,\u5982\u679c\u8bf4\u80fd\u591f\u51fb\u8d25\u8fd9\u4e2a\u6570\u636e\u7684\u8bdd\uff0c\u90a3\u8bf4\u660eDS-8201\u8054\u7528\u5e15\u59a5\u73e0\u5355\u6297\u7684\u6570\u636e\u5c06\u975e\u5e38\u8d85\u8fc7\u4e0a\u8ff0THP\u7684mPFS\u3002\u5177\u4f53\u80fd\u8d85\u8fc7\u591a\u5c11\u5462\uff1f\u5f53\u7136\u73b0\u5728\u963f\u65af\u5229\u5eb7\u8fd9\u91cc\u53ea\u662f\u8bf4\u4e2d\u671f\u7ed3\u679c\u975e\u5e38\u597d\uff0c\u90a3\u5c31\u662f\u8bf4\u660emPFS\u6570\u636e\u6709\u7740\u663e\u8457\u610f\u4e49\uff0c\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\uff0c\u4fdd\u5b88\u4f30\u8ba1HR\u8981\u8fbe\u52300.8\uff0cmPFS\u53ef\u80fd\u9700\u8981\u8fbe\u523023\u4e2a\u6708\u3002\u5f53\u7136\uff0c\u53ef\u80fd\u6839\u672c\u4e0d\u6b620.8\uff0c\u6bd5\u7adf\u963f\u65af\u5229\u5eb7\u7684\u516c\u544a\u4e2d\u63d0\u5230\uff0c\u8fd9\u6b21\u7ed3\u679c\u5177\u6709\u9ad8\u5ea6\uff08highly\uff09\u5dee\u5f02\u5316\u7684\u7edf\u8ba1\u5b66\u610f\u4e49\uff0c\u6211\u4eec\u751a\u81f3\u53ef\u4ee5\u628aHR\u5f800.7\u5f80\u4e0a\u4f30\u8ba1\u3002,\u518d\u8bf4trodelvy\u3002trodelvy\u9009\u62e9\u4e09\u9634\u6027\u4e73\u817a\u764c\u8fdb\u884c\u5207\u5165\uff0c\u76ee\u524d\u4e5f\u5356\u4e86\u56db\u4e94\u5e74\uff0c\u4f46\u9500\u552e\u989d\u4e00\u76f4\u5904\u4e8e\u4e0d\u6e29\u4e0d\u706b\u7684\u72b6\u6001\uff0c\u9664\u4e86TNBC\u5e02\u573a\u4e0d\u7b97\u5927\u4e4b\u5916\uff0c\u6700\u91cd\u8981\u7684\u539f\u56e0\uff0c\u5c31\u662f\u5b83\u4e00\u76f4\u5904\u4e8e\u540e\u7ebf\u6cbb\u7597\u3002trodelvy\u5219\u76ee\u524d\u8fd8\u572815\u4ebf\u7f8e\u5143\u5de6\u53f3\u7684\u5708\u5b50\u91cc\u6253\u8f6c\u8f6c\u3002,\u60f3\u5356\u7684\u66f4\u591a\uff0c\u5f80\u4e00\u7ebf\u63a8\u662f\u5fc5\u987b\u7684\u3002,\u5b83\u7684\u5bf9\u7167\u7ec4\u2014\u2014K\u836f\uff0b\u5316\u7597\u8054\u7528\u6b64\u524d\u4e5f\u6709\u8fc7\u4e09\u671f\u4e34\u5e8a\uff0c\u53ef\u4ee5\u53c2\u8003\u6b64\u524d\u7684\u6570\u636e\u3002\u57fa\u7ebf\u4e5f\u662fCPS\uff1e10\u7684TNBC\u60a3\u8005\u3002\u5728CPS-10\u4e9a\u7ec4\u4e2d\uff0c\u5316\u7597\uff0bK\u836f\u7684mOS\u8fbe\u5230\u4e8623\u4e2a\u6708\uff08HR=0.73\uff09\uff0cmPFS\u4e3a9.7\u4e2a\u6708\uff08HR=0.66\uff09\u3002,\"2025423819547705\",\uff08\u56fe\u7247\u6765\u6e90\uff1aPembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer\uff09,\u6839\u636e\u5409\u5229\u5fb7\u7684\u8bf4\u6cd5\uff0c\u505a\u51fa\u4e86\u7edf\u8ba1\u5b66\u7684\u5dee\u5f02\uff0c\u90a3\u548cK\u836f\uff0b\u5316\u7597\u6bd4\u8d77\u6765\uff0cmPFS\u7684\u5dee\u8ddd\u81f3\u5c11\u53ef\u4ee5\u57280.8\u5de6\u53f3\uff0c\u5927\u6982\u770b\u52300.75-0.85\u4e4b\u95f4\u3002,02<\/strong>,\u91cd\u8981\u610f\u4e49\u5176\u4e00<\/strong>
\n\u2014\u2014<\/strong>
\nADC<\/strong>
\n\u5411\u524d\u63a8\u8fdb<\/strong>,\u524d\u6587\u4e2d\u4e5f\u5728\u4e0d\u65ad\u5f3a\u8c03\u8fd9\u4ef6\u4e8b\uff0cADC\u5b83\u8981\u8d70\u7684\u8def\uff0c\u5fc5\u7136\u662f\u4e0d\u65ad\u5411\u524d\u63a8\u8fdb\u6cbb\u7597\u7ebf\u6570\u3002\u56e0\u4e3a\u5b83\u4e0d\u662fPD-1\uff0c\u5c24\u5176\u5bf9\u4e8eher2 ADC\u6765\u8bf4\uff0c\u5b83\u80fd\u6a2a\u5411\u62d3\u5c55\u7684\u764c\u79cd\u4e0d\u7b97\u591a\uff0c\u6240\u4ee5\u7eb5\u5411\u4e0d\u65ad\u5411\u524d\u63a8\u8fdb\u6cbb\u7597\u7ebf\u6570\uff0c\u63a2\u7d22\u5728\u5355\u4e00\u764c\u79cd\u4e0a\u7684\u5168\u65b0\u8054\u7528\u65b9\u6848\uff0c\u662fADC\u62d3\u5c55\u9002\u5e94\u75c7\u6218\u7565\u7684\u4e3b\u8981\u9009\u62e9\u4e4b\u4e00\u3002,\u6b64\u524d\u6709\u8fc7T-DM1\u8fdb\u884c\u8fc7\u6b64\u65b9\u9762\u7684\u5c1d\u8bd5\uff0c\u4f46\u662f\u6548\u679c\u4e0d\u7b97\u5f88\u597d\u3002\u6839\u636eT-DM1\u7684\u4e00\u7ebf\u6cbb\u7597\u4e73\u817a\u764c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u2014\u2014MARIANNE\u6765\u770b\uff0c\u4e0e\u66f2\u59a5\u73e0\u5355\u6297\u52a0\u7d2b\u6749\u70f7\u7c7b\u6cbb\u7597\u76f8\u6bd4\uff0cT-DM1\u5355\u836f\u6cbb\u7597\u4e0eT-DM1\uff0b\u5e15\u59a5\u73e0\u5355\u6297\u8054\u7528\u6cbb\u7597\u5747\u6ca1\u6709\u663e\u793a\u51fa\u5dee\u5f02\u5316\u7684\u7597\u6548\uff0cHR\u5206\u522b\u4e3a0.91\u548c0.87\uff0c\u8be5\u4e34\u5e8a\u65f6\u95f4\u8de8\u5ea6\u4e3a2010\u5e74\u52302012\u5e74\uff0c\u8fd9\u4e3a\u5f53\u65f6ADC\u836f\u7269\u63a8\u8fdb\u81f3\u4e00\u7ebf\u6cbb\u7597\u8499\u4e0a\u4e86\u4e00\u5c42\u7eb1\u3002,\u5b9e\u4f53\u7624\u65b9\u9762\u7684ADC\u6765\u770b\uff0c\u518d\u5f80\u540e\u9762\u6570\uff0c\u5c31\u8981\u6570\u5230\u8f89\u745e\u7684padcev\u4e86\u3002padcev\uff0bK\u836f\u7528\u4e8e\u4e00\u7ebf\u6cbb\u7597\u5c3f\u8def\u4e0a\u76ae\u764c\u76ee\u524d\u5df2\u7ecf\u83b7\u6279\uff0c\u4e0d\u8fc7\u83b7\u6279\u9488\u5bf9\u7684\u662fIb\/II\u671f\u4e34\u5e8a\uff0c\u800c\u4e0d\u662f\u4e09\u671f\u4e34\u5e8a\u3002\u4e34\u5e8a\u7ed3\u679c\u76f4\u63a5\u770b\u56fe\uff0c\u5373\u4fbf\u5bf9\u4e8e\u4e00\u7ebf\u6cbb\u7597\u6765\u8bf4\u7ed3\u679c\u4e5f\u975e\u5e38\u60ca\u8273\uff0c\u800c\u4e14\u6709ADC\uff0b\u5316\u7597\u7ec4\u7684\u5bf9\u7167\uff0ccORR\u6cbb\u7597\u7ec4\u8fbe\u5230\u4e8664.5\uff0c\u5bf9\u7167\u7ec4\u4e3a45.2%\u3002\u518d\u770b\u4e0b\u9762\u7011\u5e03\u56fe\uff0c97.1%\u7684\u60a3\u8005\u5b9e\u73b0\u4e86\u80bf\u7624\u7684\u7f29\u5c0f\u3002,\"2025423819547784\",\uff08\u56fe\u7247\u6765\u6e90\uff1aEnfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer\uff09,\u57fa\u4e8e\u6b64\uff0cFDA\u52a0\u901f\u6279\u51c6\u4e86K\u836f\uff0bpadcev\u8054\u5408\u7597\u6cd5\u7528\u4e8e\u4e00\u7ebf\u6cbb\u7597\u5c3f\u8def\u4e0a\u76ae\u764c\u3002\u5f53\u7136\uff0c\u8fd9\u4e2a\u610f\u4e49\u4e0d\u6b62\u662f\u5728ADC\u7597\u6cd5\u7684\u63a8\u8fdb\u4e0a\uff0c\u66f4\u662f\u5728IO\uff0bADC\u7684\u8054\u7528\u4e0a\u3002,\u518d\u5f80\u540e\u5c31\u662f\u4eca\u5929\u6700\u8fd1\u51e0\u5929\u53d1\u751f\u7684\u201c\u5f53\u4ee3\u53f2\u201d\u4e86\u3002DS-8201\u7ec8\u4e8e\u65a9\u83b7\u4e86\u4e73\u817a\u764c\u7684\u4e00\u7ebf\u6cbb\u7597\u901a\u884c\u8bc1\u3002trodelvy\u4e5f\u83b7\u5f97\u4e86\u68a6\u5bd0\u4ee5\u6c42\u7684\u8fdb\u5165TNBC\u4e00\u7ebf\u6cbb\u7597\u95e8\u69db\u7684\u8d44\u683c\u3002,ADC\u7684\u5176\u4e2d\u4e00\u4e2a\u613f\u666f\u2014\u2014\u4ece\u540e\u7ebf\u5411\u524d\u7ebf\u63a8\u8fdb\uff0c\u6b63\u5728\u4ece\u7406\u60f3\u53d8\u6210\u73b0\u5b9e\u3002,03<\/strong>,\u91cd\u8981\u610f\u4e49\u5176\u4e8c<\/strong>
\n\u2014\u2014<\/strong>
\nADC<\/strong>
\n\uff0b<\/strong>
\nIO<\/strong>,\u6211\u4eec\u66fe\u4e0d\u6b62\u4e00\u6b21\u5f3a\u8c03\uff0cPD-1\u7c7b\u578b\u7684\u5355\u6297\u4e0d\u8bf4\u672a\u6765\uff0c\u81f3\u5c11\u662f\u76ee\u524d\u80bf\u7624\u6cbb\u7597\u7684\u57fa\u77f3\uff0cK\u836f\u662f\u76ee\u524d\u7684\u4e07\u7cbe\u6cb9\uff0c\u53ef\u4ee5\u7528\u4e8e\u7edd\u5927\u591a\u6570\u764c\u79cd\u3002\u4f46ADC\u7684\u764c\u79cd\u76ee\u524d\u53d7\u5230\u8f83\u591a\u9650\u5236\u3002\u4f46\u7ec8\u5f52\u6765\u8bf4\uff0cADC\u4ece\u539f\u7406\u4e0a\u662f\u6bd4\u5316\u7597\u66f4\u5b89\u5168\u7684\uff0cADC\u53bb\u8fed\u4ee3\u5316\u7597\uff0c\u4e0ePD-1\u8fdb\u884c\u8054\u7528\uff0c\u5c06\u4f1a\u91cd\u5851\u764c\u75c7\u6cbb\u7597\u7684\u683c\u5c40\uff0c\u6210\u4e3a\u764c\u75c7\u6cbb\u7597\u65b0\u7684\u57fa\u77f3\u3002,\u5728\u8fd9\u70b9\u4e0a\uff0c\u6211\u4eec\u66fe\u7ecf\u5728\u8bf8\u591a\u6587\u7ae0\u91cc\u9762\u5f3a\u8c03\u6b64\u4e8b\uff0c\u4f8b\u5982\u300a\u300b\u4e2d\u6709\u8fc7\u8be6\u5c3d\u7684\u53d9\u8ff0\uff0c\u5173\u4e8eBioNTech\u6536\u8d2d\u666e\u7c73\u65af\uff0c\u5c06PM8002\u4f5c\u4e3abackbone drug\u53bb\u53d1\u5c55\uff0c\u5e76\u4e14\u76ee\u524d\u5df2\u7ecf\u5728\u5f00\u5c55\u4e0etrop2 ADC\u7684\u8054\u7528\u3002,\u6700\u8fd1\u6570\u65e5\u53d1\u751f\u7684\u4e8b\u60c5\uff0c\u53ea\u662f\u5bf9\u6b64\u524d\u53d9\u4e8b\u7684\u4e00\u4e9b\u5370\u8bc1\u3002trodelvy\u4e0eK\u836f\u8054\u7528\u8fbe\u5230\u4e86\u5dee\u5f02\u5316\u7684\u7597\u6548\uff0c\u8fd9\u4ef6\u4e8b\u76f8\u6bd4\u4e8epadcev\uff0bK\u836f\u8fd8\u662f\u6709\u8f83\u5927\u533a\u522b\uff0c\u56e0\u4e3a\u524d\u8005\u662f\u4e09\u671f\u4e34\u5e8a\uff0c\u662f\u771f\u6b63\u7684\u4e00\u9524\u5b9a\u97f3\uff0c\u5728\u6700\u540e\u4e34\u95e8\u4e00\u811a\u4e0a\u9a8c\u8bc1\u4e86\u8be5\u7597\u6cd5\u4e0e\u5316\u7597\uff0bK\u836f\u76f8\u6bd4\u7684\u4f18\u8d8a\u6027\u3002,\u7ed3\u8bed\uff1a<\/strong>\u4e0d\u7ba1\u662fADC\u6cbb\u7597\u7ebf\u6570\u5411\u524d\u63a8\u8fdb\uff0c\u8fd8\u662fIO\uff0bADC\u8054\u7528\uff0c\u4e24\u4e2a\u8d8b\u52bf\u90fd\u662f\u533b\u836f\u53f2\u8bd7\u7684\u5fc5\u7136\u8fdb\u7a0b\uff0c\u5927\u52bf\u6240\u8d8b\uff0c\u4e0d\u53ef\u963b\u6321\uff0c\u53ea\u662f\u6211\u4eec\u671f\u5f85\u7684\u662f\u672a\u6765\u51fa\u73b0\u66f4\u591aHR\u663e\u8457\u7684\u7ed3\u679c\uff0c\u6765\u8fdb\u884c\u529b\u5ea6\u66f4\u52a0\u5145\u5206\u7684\u9a8c\u8bc1\u3002,IO+ADC\u4e3a\u80bf\u7624\u6cbb\u7597\u5e26\u6765\u4e86\u4e00\u4e2a\u65b0\u7684\u65f6\u4ee3\uff0cADC\u7684\u84ec\u52c3\u53d1\u5c55\u4e5f\u5728\u8fed\u4ee3\u5316\u7597\u8fd9\u4e2a\u80bf\u7624\u6cbb\u7597\u7684\u4f20\u7edf\u57fa\u77f3\uff0c\u521b\u65b0\u836f\u76ee\u524d\u771f\u7684\u5728\u4e00\u6b65\u6b65\u505a\u7740\u201c\u6562\u6559\u65e5\u6708\u6362\u65b0\u5929\u201d\u7684\u4e8b\u4e1a\u3002,\u3010\u672c\u6587\u7531\u6295\u8d44\u754c\u5408\u4f5c\u4f19\u4f34\u5fae\u4fe1\u516c\u4f17\u53f7\uff1a\u77aa\u7f9a\u793e\u6388\u6743\u53d1\u5e03\uff0c\u672c\u5e73\u53f0\u4ec5\u63d0\u4f9b\u4fe1\u606f\u5b58\u50a8\u670d\u52a1\u3002\u3011\u5982\u6709\u4efb\u4f55\u7591\u95ee\uff0c\u8bf7\u8054\u7cfb\uff08editor@zero2ipo.com.cn\uff09\u6295\u8d44\u754c\u5904\u7406\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"

\u6700\u8fd1\u6570\u65e5\uff0cADC\u836f\u7269\u65b9\u9762\u7684\u597d\u6d88\u606f\u63a5\u8fde\u4e0d\u65ad\u3002,\u963f\u65af\u5229\u5eb7\/*\u4e09\u5171\u65b9\u9762\uff0c4\u670821\u65e5\uff0c\u5176\u5ba3\u5e03DS-8201\u8054\u7528\u5e15\u59a5\u73e0\u5355…<\/p>\n","protected":false},"author":277,"featured_media":6315,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-5960","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"_links":{"self":[{"href":"http:\/\/www.yuntou8.com\/index.php?rest_route=\/wp\/v2\/posts\/5960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.yuntou8.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.yuntou8.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.yuntou8.com\/index.php?rest_route=\/wp\/v2\/users\/277"}],"replies":[{"embeddable":true,"href":"http:\/\/www.yuntou8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5960"}],"version-history":[{"count":1,"href":"http:\/\/www.yuntou8.com\/index.php?rest_route=\/wp\/v2\/posts\/5960\/revisions"}],"predecessor-version":[{"id":6318,"href":"http:\/\/www.yuntou8.com\/index.php?rest_route=\/wp\/v2\/posts\/5960\/revisions\/6318"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.yuntou8.com\/index.php?rest_route=\/wp\/v2\/media\/6315"}],"wp:attachment":[{"href":"http:\/\/www.yuntou8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.yuntou8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5960"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.yuntou8.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}